Cancer stem cells: A new target for lung cancer treatment;Cellules souches cancéreuses: Nouvelle cible thérapeutique dans le traitement des cancers bronchopulmonaires

Cancer/Radiotherapie

Volumn 15, Issue 5, 2011, Pages 355-364

  Rivera, S ^a,b   Rivera, C ^a,c   Loriot, Y ^a   Hennequin, C ^b   Vozenin, M C ^a   Deutsch, E ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c HAUT LÉVÊQUE HOSPITAL   (France)

Author keywords

Cancer stem cell; Lung carcinoma; Preclinical models; Radioresistance; Radiosensitivity; Stem cell; Therapeutic target

Indexed keywords

CELL MARKER;

CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER RESISTANCE; CANCER STEM CELL; CELL ISOLATION; DATA ANALYSIS; DISEASE COURSE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; LUNG TUMOR; MEDICAL RECORD; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; RADIOSENSITIVITY; SHORT SURVEY; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION;

ANIMALS; ANTIGENS, DIFFERENTIATION; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL TRANSDIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; DRUG RESISTANCE, NEOPLASM; EPITHELIAL CELLS; HUMANS; LUNG; LUNG NEOPLASMS; MICE; MODELS, ANIMAL; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; NEOPLASTIC STEM CELLS; PROGNOSIS; RADIATION TOLERANCE; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 79961208051     PISSN: 12783218     EISSN: 17696658     Source Type: Journal    
DOI: 10.1016/j.canrad.2011.03.003     Document Type: Short Survey

References (123)

1. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
2. Nowell P.C. The clonal evolution of tumor cell populations. Science 1976, 194:23-28.
3. Wicha M.S., Liu S., Dontu G. Cancer stem cells: an old idea-a paradigm shift. Cancer Res 2006, 66:1883-1890. [discussion 1895-1886].
4. Campbell L.L., Polyak K. Breast tumor heterogeneity: cancer stem cells or clonal evolution?. Cell Cycle 2007, 6:2332-2338.
5. Visvader J.E., Lindeman G.J. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008, 8:755-768.
6. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003, 100:3983-3988.
7. Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., et al. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
8. Collins A.T., Maitland N.J. Prostate cancer stem cells. Eur J Cancer 2006, 42:1213-1218.
9. Hermann P.C., Huber S.L., Herrler T., Aicher A., Ellwart J.W., Guba M., et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007, 1:313-323.
10. Ricci-Vitiani L., Lombardi D.G., Pilozzi E., Biffoni M., Todaro M., Peschle C., et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007, 445:111-115.
11. Eramo A., Lotti F., Sette G., Pilozzi E., Biffoni M., Di Virgilio A., et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008, 15:504-514.
12. Jordan C.T., Guzman M.L., Noble M. Cancer stem cells. N Engl J Med 2006, 355:1253-1261.
13. Lobo N.A., Shimono Y., Qian D., Clarke M.F. The biology of cancer stem cells. Ann Rev Cell Dev Biol 2007, 23:675-699.
14. Scadden D.T. The stem-cell niche as an entity of action. Nature 2006, 441:1075-1079.
15. Zhu X, Zhou X, Lewis MT, Xia L, Wong S. Cancer stem cell, niche and EGFR decide tumor development and treatment response: a bio-computational simulation study. J Theor Biol 2011;269:138-49.
16. Albini A, Cesana E, Noonan DM. Cancer stem cells and the tumor microenvironment: soloists or choral singers? Curr Pharm Biotechnol 2011;12(2):171-81.
17. Clarke M.F., Fuller M. Stem cells and cancer: two faces of eve. Cell 2006, 124:1111-1115.
18. Calabrese C., Poppleton H., Kocak M., Hogg T.L., Fuller C., Hamner B., et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007, 11:69-82.
19. Parmar K., Mauch P., Vergilio J.A., Sackstein R., Down J.D. Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci U S A 2007, 104:5431-5436.
20. Mazumdar J, O'Brien WT, Johnson RS, LaManna JC, Chavez JC, Klein PS, et al. O2 regulates stem cells through Wnt/beta-catenin signalling. Nat Cell Biol 2010;12:1007-13.
21. Lapidot T., Sirard C., Vormoor J., Murdoch B., Hoang T., Caceres-Cortes J., et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367:645-648.
22. Reynolds B.A., Rietze R.L. Neural stem cells and neurospheres-re-evaluating the relationship. Nat Methods 2005, 2:333-336.
23. Debeb B.G., Xu W., Woodward W.A. Radiation resistance of breast cancer stem cells: understanding the clinical framework. J Mammary Gland Biol Neoplasia 2009, 14:11-17.
24. Li X., Lewis M.T., Huang J., Gutierrez C., Osborne C.K., Wu M.F., et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008, 100:672-679.
25. Al-Assar O., Muschel R.J., Mantoni T.S., McKenna W.G., Brunner T.B. Radiation response of cancer stem-like cells from established human cell lines after sorting for surface markers. Int J Radiat Oncol Biol Phys 2009, 75:1216-1225.
26. Baumann M., Krause M., Hill R. Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer 2008, 8:545-554.
27. Zhang M, Atkinson RL, Rosen JM. Selective targeting of radiation-resistant tumor-initiating cells. Proc Natl Acad Sci USA 2010;107:3522-527.
28. Martin L.P., Hamilton T.C., Schilder R.J. Platinum resistance: the role of DNA repair pathways. Clin Cancer Res 2008, 14:1291-1295.
29. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760.
30. Goodell M.A., Brose K., Paradis G., Conner A.S., Mulligan R.C. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 1996, 183:1797-1806.
31. Ding XW, Wu JH, Jiang CP. ABCG2: a potential marker of stem cells and novel target in stem cell and cancer therapy. Life Sci 2010;86:631-7.
32. Zhou S., Schuetz J.D., Bunting K.D., Colapietro A.M., Sampath J., Morris J.J., et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 2001, 7:1028-1034.
33. Ryan D.H., Chapple C.W., Kossover S.A., Sandberg A.A., Cohen H.J. Phenotypic similarities and differences between CALLA-positive acute lymphoblastic leukemia cells and normal marrow CALLA-positive B cell precursors. Blood 1987, 70:814-821.
34. Tirino V., Camerlingo R., Franco R., Malanga D., La Rocca A., Viglietto G., et al. The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer. Eur J Cardiothorac Surg 2009, 36:446-453.
35. Yu Y., Flint A., Dvorin E.L., Bischoff J. AC133-2, a novel isoform of human AC133 stem cell antigen. J Biol Chem 2002, 277:20711-20716.
36. Taieb N., Maresca M., Guo X.J., Garmy N., Fantini J., Yahi N. The first extracellular domain of the tumour stem cell marker CD133 contains an antigenic ganglioside-binding motif. Cancer Lett 2009, 278:164-173.
37. Klonisch T., Wiechec E., Hombach-Klonisch S., Ande S.R., Wesselborg S., Schulze-Osthoff K., et al. Cancer stem cell markers in common cancers - therapeutic implications. Trends Mol Med 2008, 14:450-460.
38. Yoshida A., Rzhetsky A., Hsu L.C., Chang C. Human aldehyde dehydrogenase gene family. Eur J Biochem 1998, 251:549-557.
39. Jones R.J., Barber J.P., Vala M.S., Collector M.I., Kaufmann S.H., Ludeman S.M., et al. Assessment of aldehyde dehydrogenase in viable cells. Blood 1995, 85:2742-2746.
40. Ginestier C., Hur M.H., Charafe-Jauffret E., Monville F., Dutcher J., Brown M., et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1:555-567.
41. Huang E.H., Hynes M.J., Zhang T., Ginestier C., Dontu G., Appelman H., et al. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res 2009, 69:3382-3389.
42. Jiang F., Qiu Q., Khanna A., Todd N.W., Deepak J., Xing L., et al. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res 2009, 7:330-338.
43. Kelly P.N., Dakic A., Adams J.M., Nutt S.L., Strasser A. Tumor growth need not be driven by rare cancer stem cells. Science 2007, 317:337.
44. Yoo M.H., Hatfield D.L. The cancer stem cell theory: is it correc. Mol Cells 2008, 26:514-516.
45. Rowan K. Are cancer stem cells real? After four decades, debate still simmers. J Natl Cancer Inst 2009, 101:546-547.
46. Baguley BC. Multiple drug resistance mechanisms in cancer. Mol Biotechnol 2010;46:308-16.
47. Berridge MV, Herst PM, Tan AS. Metabolic flexibility and cell hierarchy in metastatic cancer. Mitochondrion 2010;10:584-8.
48. Aguirre-Ghiso J.A. The problem of cancer dormancy: understanding the basic mechanisms and identifying therapeutic opportunities. Cell Cycle 2006, 5:1740-1743.
49. Collins L.G., Haines C., Perkel R., Enck R.E. Lung cancer: diagnosis and management. Am Fam Physician 2007, 75:56-63.
50. Brambilla E., Veale D., Moro D., Morel F., Dubois F., Brambilla C. Neuroendocrine phenotype in lung cancers. Comparison of immunohistochemistry with biochemical determination of enolase isoenzymes. Am J Clin Pathol 1992, 98:88-97.
51. Yanada M., Yaoi T., Shimada J., Sakakura C., Nishimura M., Ito K., et al. Frequent hemizygous deletion at 1p36 and hypermethylation downregulate RUNX3 expression in human lung cancer cell lines. Oncol Rep 2005, 14:817-822.
52. Hiyama K., Hiyama E., Ishioka S., Yamakido M., Inai K., Gazdar A.F., et al. Telomerase activity in small-cell and non-small-cell lung cancers. J Natl Cancer Inst 1995, 87:895-902.
53. Amos C.I., Xu W., Spitz M.R. Is there a genetic basis for lung cancer susceptibility?. Recent Results Cancer Res 1999, 151:3-12.
54. Metzger R.J., Klein O.D., Martin G.R., Krasnow M.A. The branching programme of mouse lung development. Nature 2008, 453:745-750.
55. Cardoso W.V., Lu J. Regulation of early lung morphogenesis: questions, facts and controversies. Development 2006, 133:1611-1624.
56. Weaver M., Batts L., Hogan B.L. Tissue interactions pattern the mesenchyme of the embryonic mouse lung. Dev Biol 2003, 258:169-184.
57. Ishii Y., Rex M., Scotting P.J., Yasugi S. Region-specific expression of chicken Sox2 in the developing gut and lung epithelium: regulation by epithelial-mesenchymal interactions. Dev Dyn 1998, 213:464-475.
58. Gontan C., de Munck A., Vermeij M., Grosveld F., Tibboel D., Rottier R. Sox2 is important for two crucial processes in lung development: branching morphogenesis and epithelial cell differentiation. Dev Biol 2008, 317:296-309.
59. Okubo T., Knoepfler P.S., Eisenman R.N., Hogan B.L. Nmyc plays an essential role during lung development as a dosage-sensitive regulator of progenitor cell proliferation and differentiation. Development 2005, 132:1363-1374.
60. Perl A.K., Wert S.E., Nagy A., Lobe C.G., Whitsett J.A. Early restriction of peripheral and proximal cell lineages during formation of the lung. Proc Natl Acad Sci U S A 2002, 99:10482-10487.
61. Pack R.J., Al-Ugaily L.H., Morris G., Widdicombe J.G. The distribution and structure of cells in the tracheal epithelium of the mouse. Cell Tissue Res 1980, 208:65-84.
62. Hong K.U., Reynolds S.D., Watkins S., Fuchs E., Stripp B.R. In vivo differentiation potential of tracheal basal cells: evidence for multipotent and unipotent subpopulations. Am J Physiol Lung Cell Mol Physiol 2004, 286:L643-649.
63. Hong K.U., Reynolds S.D., Watkins S., Fuchs E., Stripp B.R. Basal cells are a multipotent progenitor capable of renewing the bronchial epithelium. Am J Pathol 2004, 164:577-588.
64. Nakanishi K., Hiroi S., Kawai T., Suzuki M., Torikata C. Argyrophilic nucleolar-organizer region counts and DNA status in bronchioloalveolar epithelial hyperplasia and adenocarcinoma of the lung. Hum Pathol 1998, 29:235-239.
65. Trichopoulos D., Mollo F., Tomatis L., Agapitos E., Delsedime L., Zavitsanos X., et al. Active and passive smoking and pathological indicators of lung cancer risk in an autopsy study. JAMA 1992, 268:1697-1701.
66. Giangreco A., Arwert E.N., Rosewell I.R., Snyder J., Watt F.M., Stripp B.R. Stem cells are dispensable for lung homeostasis but restore airways after injury. Proc Natl Acad Sci U S A 2009, 106:9286-9291.
67. Evans M.J., Cabral-Anderson L.J., Freeman G. Role of the Clara cell in renewal of the bronchiolar epithelium. Lab Invest 1978, 38:648-653.
68. Giangreco A., Reynolds S.D., Stripp B.R. Terminal bronchioles harbor a unique airway stem cell population that localizes to the bronchoalveolar duct junction. Am J Pathol 2002, 161:173-182.
69. Reynolds S.D., Giangreco A., Power J.H., Stripp B.R. Neuroepithelial bodies of pulmonary airways serve as a reservoir of progenitor cells capable of epithelial regeneration. Am J Pathol 2000, 156:269-278.
70. Stevens T.P., McBride J.T., Peake J.L., Pinkerton K.E., Stripp B.R. Cell proliferation contributes to PNEC hyperplasia after acute airway injury. Am J Physiol 1997, 272:L486-L493.
71. Linnoila R.I., Jensen S.M., Steinberg S.M., Mulshine J.L., Eggleston J.C., Gazdar A.F. Peripheral airway cell marker expression in non-small cell lung carcinoma. Association with distinct clinicopathologic features. Am J Clin Pathol 1992, 97:233-243.
72. Eisenberg L.M., Eisenberg C.A. Stem cell plasticity, cell fusion, and transdifferentiation. Birth Defects Res C Embryo Today 2003, 69:209-218.
73. Forbes S.J., Vig P., Poulsom R., Wright N.A., Alison M.R. Adult stem cell plasticity: new pathways of tissue regeneration become visible. Clin Sci (Lond) 2002, 103:355-369.
74. Kim C.F., Jackson E.L., Woolfenden A.E., Lawrence S., Babar I., Vogel S., et al. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 2005, 121:823-835.
75. Onuki N., Wistuba I.I., Travis W.D., Virmani A.K., Yashima K., Brambilla E., et al. Genetic changes in the spectrum of neuroendocrine lung tumors. Cancer 1999, 85:600-607.
76. Meuwissen R., Berns A. Mouse models for human lung cancer. Genes Dev 2005, 19:643-664.
77. Ohtsuka N., Urase K., Momoi T., Nogawa H. Induction of bud formation of embryonic mouse tracheal epithelium by fibroblast growth factor plus transferrin in mesenchyme-free culture. Dev Dyn 2001, 222:263-272.
78. Giangreco A., Groot K.R., Janes S.M. Lung cancer and lung stem cells: strange bedfellows?. Am J Respir Crit Care Med 2007, 175:547-553.
79. Ho M.M., Ng A.V., Lam S., Hung J.Y. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res 2007, 67:4827-4833.
80. Summer R., Kotton D.N., Sun X., Ma B., Fitzsimmons K., Fine A. Side population cells and Bcrp1 expression in lung. Am J Physiol Lung Cell Mol Physiol 2003, 285:L97-104.
81. Sung J.M., Cho H.J., Yi H., Lee C.H., Kim H.S., Kim D.K., et al. Characterization of a stem cell population in lung cancer A549 cells. Biochem Biophys Res Commun 2008, 371:163-167.
82. Salcido CD, Larochelle A, Taylor BJ, Dunbar CE, Varticovski L. Molecular characterisation of side population cells with cancer stem cell-like characteristics in small-cell lung cancer. Br J Cancer 2010;102:1636-44.
83. Eramo A, Haas TL, De Maria R. Lung cancer stem cells: tools and targets to fight lung cancer. Oncogene 2010;29:4625-35.
84. Levina V., Marrangoni A.M., DeMarco R., Gorelik E., Lokshin A.E. Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS One 2008, 3:e3077.
85. Chen Y.C., Hsu H.S., Chen Y.W., Tsai T.H., How C.K., Wang C.Y., et al. Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoS One 2008, 3:e2637.
86. Bertolini G., Roz L., Perego P., Tortoreto M., Fontanella E., Gatti L., et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci U S A 2009, 106:16281-16286.
87. Tirino V., Desiderio V., d'Aquino R., De Francesco F., Pirozzi G., Graziano A., et al. Detection and characterization of CD133+ cancer stem cells in human solid tumours. PLoS One 2008, 3:e3469.
88. Salnikov AV, Gladkich J, Moldenhauer G, Volm M, Mattern J, Herr I. CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients. Int J Cancer 2010;126:950-8.
89. Li F., Zeng H., Ying K. The combination of stem cell markers CD133 and ABCG2 predicts relapse in stage I non-small cell lung carcinomas. Med Oncol 2010, [sous presse]. 10.1007/s12032-010-9646-5.
90. Bonnefoix T., Bonnefoix P., Verdiel P., Sotto J.J. Fitting limiting dilution experiments with generalized linear models results in a test of the single-hit Poisson assumption. J Immunol Methods 1996, 194:113-119.
91. Phillips T.M., McBride W.H., Pajonk F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 2006, 98:1777-1785.
92. Diehn M., Clarke M.F. Cancer stem cells and radiotherapy: new insights into tumor radioresistance. J Natl Cancer Inst 2006, 98:1755-1757.
93. Wollman R., Yahalom J., Maxy R., Pinto J., Fuks Z. Effect of epidermal growth factor on the growth and radiation sensitivity of human breast cancer cells in vitro. Int J Radiat Oncol Biol Phys 1994, 30:91-98.
94. Paris F., Fuks Z., Kang A., Capodieci P., Juan G., Ehleiter D., et al. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 2001, 293:293-297.
95. Clarke M.F., Dick J.E., Dirks P.B., Eaves C.J., Jamieson C.H., Jones D.L., et al. Cancer stem cells - perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006, 66:9339-9344.
96. Yaromina A., Zips D., Thames H.D., Eicheler W., Krause M., Rosner A., et al. Pimonidazole labelling and response to fractionated irradiation of five human squamous cell carcinoma (hSCC) lines in nude mice: the need for a multivariate approach in biomarker studies. Radiother Oncol 2006, 81:122-129.
97. Nordsmark M., Bentzen S.M., Rudat V., Brizel D., Lartigau E., Stadler P., et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 2005, 77:18-24.
98. Overgaard J. Hypoxic radiosensitization: adored and ignored. J Clin Oncol 2007, 25:4066-4074.
99. Covello K.L., Kehler J., Yu H., Gordan J.D., Arsham A.M., Hu C.J., et al. HIF-2alpha regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev 2006, 20:557-570.
100. Bernier J., Hall E.J., Giaccia A. Radiation oncology: a century of achievements. Nat Rev Cancer 2004, 4:737-747.
101. Krause M., Zips D., Thames H.D., Kummermehr J., Baumann M. Preclinical evaluation of molecular-targeted anticancer agents for radiotherapy. Radiother Oncol 2006, 80:112-122.
102. Bishop J.M. The molecular genetics of cancer. Science 1987, 235:305-311.
103. Cameron E.R., Neil J.C. The Runx genes: lineage-specific oncogenes and tumor suppressors. Oncogene 2004, 23:4308-4314.
104. de Guzman C.G., Warren A.J., Zhang Z., Gartland L., Erickson P., Drabkin H., et al. Hematopoietic stem cell expansion and distinct myeloid developmental abnormalities in a murine model of the AML1-ETO translocation. Mol Cell Biol 2002, 22:5506-5517.
105. Lee KS, Lee YS, Lee JM, Ito K, Cinghu S, Kim JH, et al. Runx3 is required for the differentiation of lung epithelial cells and suppression of lung cancer. Oncogene 2010;29:3349-61.
106. Li Q.L., Kim H.R., Kim W.J., Choi J.K., Lee Y.H., Kim H.M., et al. Transcriptional silencing of the RUNX3 gene by CpG hypermethylation is associated with lung cancer. Biochem Biophys Res Commun 2004, 314:223-228.
107. Licchesi J.D., Westra W.H., Hooker C.M., Machida E.O., Baylin S.B., Herman J.G. Epigenetic alteration of Wnt pathway antagonists in progressive glandular neoplasia of the lung. Carcinogenesis 2008, 29:895-904.
108. Kwei K.A., Kim Y.H., Girard L., Kao J., Pacyna-Gengelbach M., Salari K., et al. Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer. Oncogene 2008, 27:3635-3640.
109. Lockwood WW, Chari R, Coe BP, Thu KL, Garnis C, Malloff CA, et al. Integrative genomic analyses identify BRF2 as a novel lineage-specific oncogene in lung squamous cell carcinoma. PLoS Med 2010;7:e1000315.
110. Zhang X, Han B, Huang J, Zheng B, Geng Q, Aziz F, et al. Prognostic Significance of OCT4 Expression in Adenocarcinoma of the Lung. Jpn J Clin Oncol 2010;40(10):961-6.
111. Karoubi G., Gugger M., Schmid R., Dutly A. OCT4 expression in human non-small cell lung cancer: implications for therapeutic intervention. Interact Cardiovasc Thorac Surg 2009, 8:393-397.
112. Hu T., Liu S., Breiter D.R., Wang F., Tang Y., Sun S. Octamer 4 small interfering RNA results in cancer stem cell-like cell apoptosis. Cancer Res 2008, 68:6533-6540.
113. Boyer L.A., Lee T.I., Cole M.F., Johnstone S.E., Levine S.S., Zucker J.P., et al. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 2005, 122:947-956.
114. Ivanova N., Dobrin R., Lu R., Kotenko I., Levorse J., DeCoste C., et al. Dissecting self-renewal in stem cells with RNA interference. Nature 2006, 442:533-538.
115. Hussenet T, Dali S, Exinger J, Monga B, Jost B, Dembele D, et al. SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung squamous cell carcinomas. PLoS One 5:e8960.
116. Lu Y, Futtner C, Rock JR, Xu X, Whitworth W, Hogan BL, et al. Evidence that SOX2 overexpression is oncogenic in the lung. PLoS One 5:e11022.
117. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126:663-676.
118. Wernig M., Meissner A., Foreman R., Brambrink T., Ku M., Hochedlinger K., et al. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature 2007, 448:318-324.
119. Krystal G.W., Hines S.J., Organ C.P. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Cancer Res 1996, 56:370-376.
120. Hines S.J., Organ C., Kornstein M.J., Krystal G.W. Coexpression of the c-kit and stem cell factor genes in breast carcinomas. Cell Growth Differ 1995, 6:769-779.
121. Yasuda A., Sawai H., Takahashi H., Ochi N., Matsuo Y., Funahashi H., et al. Stem cell factor/c-kit receptor signaling enhances the proliferation and invasion of colorectal cancer cells through the PI3K/Akt pathway. Dig Dis Sci 2007, 52:2292-2300.
122. Hassan H.T. c-Kit expression in human normal and malignant stem cells prognostic and therapeutic implications. Leuk Res 2009, 33:5-10.
123. Levina V, Marrangoni A, Wang T, Parikh S, Su Y, Herberman R, et al. Elimination of human lung cancer stem cells through targeting of the stem cell factor-c-kit autocrine signaling loop. Cancer Res 2010;70:338-46.